Q-omics provides the consensus-scored ZNF663P profile across patient tissues and cancer cell-line models. ZNF663P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF663P is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF663P RNA expression shows 16,731 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where ZNF663P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF663P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF663P survival associations across molecular data types. ZNF663P RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF663P RNA expression–survival associations across cancer types. High ZNF663P expression shows unfavorable associations in UCEC and STAD, but favorable associations in KIRP, UVM, UCS and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF663P RNA expression.
This table summarizes ZNF663P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF663P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF663P shows lower tumor expression in KIRC, KICH, UCEC, BRCA, THCA and HNSC. The KIRC box plot shows higher ZNF663P RNA expression in normal versus tumor tissue (log2 FC = −0.597, t-test p < 0.001).
This table shows molecular features associated with ZNF663P in patient tissues and cancer cell lines. In patient samples, ZNF663P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF663P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
